Institute of Mental Health

 

 

 

The UBC Institute of Mental Health (IMH) is home to a community of clinicians and scientists committed to re-examining the field of mental health and mental illness, and seeking new insights into the diagnosis and treatment of some of the most challenging issues in modern medicine. Their activities include:

  • Building on recent advances in the fields of neuroscience, genetics, pathology, brain imaging, psychology and epidemiology;
  • Translating these advances into clinically effective preventive and treatment strategies including early intervention, psychotherapy, genetic counseling and medications;
  • Ensuring, through training and education, their application in everyday clinical practice throughout British Columbia.

The Institute of Mental Health endowment was established to support leading edge research in child and adolescent psychiatry, psychotherapy, and geriatric psychiatry. As more resources become available, the breadth of activities has grown.

As an integral part of UBC’s Department of Psychiatry, the Institute of Mental Health’s interdisciplinary activities include over 90 basic and clinical researchers in the Faculties of Medicine, Science, Nursing, Education, Law and Arts.

Director (May 2018 - June 2021)

Dr. Lakshmi Yatham MBBS, DPM, FRCPC, MBA (Exec)

Department Head and Professor, Department of Psychiatry, Faculty of Medicine, UBC;
Regional Head of Psychiatry and Regional Program Medical Director, Vancouver Coastal Health & Providence Healthcare

In his role as Director, UBC Institute of Mental Health, Dr. Yatham will provide leadership in teaching and research, and in promoting and improving patient care and clinical service delivery, working in partnership with affiliated Health Authorities across B.C.

Dr. Yatham, Professor in the Department of Psychiatry, is also the Regional Head of Psychiatry and Regional Program Medical Director for Mental Health and Addictions at Vancouver Coastal Health and Providence Health Care. He has held leadership positions for national and international professional organizations including President of the International Society for Bipolar Disorders, Secretary for the World Federation of Societies of Biological Psychiatry (SFSBP), and is now the President-Elect for the SFSBP. Dr. Yatham’s major areas of research interest include neurobiology and treatment of bipolar disorder and major depression.

Past Directors

William G. Honer, MD, FRCPC, FCAHS (October 2011 - December 2016)

William HonerDr. Honer is a Professor and Head of the Department of Psychiatry and the Jack Bell Chair in Schizophrenia. He is also the Scientific Director of the BC Mental Health & Addictions Research Institute.

Dr. Honer received his medical degree from Queen’s University. He completed specialty training in psychiatry at Vancouver General Hospital and the New York State Psychiatric Institute/ Columbia University. This was followed by research training in neuropathology and genetics at Columbia University and the Albert Einstein College of Medicine. His research interests include mechanisms of illness in schizophrenia, brain aging and complex co-occurring illnesses such as psychosis, addiction and infectious disease. He is the author of more than 200 peer-reviewed publications and has authored the assessment section of the Canadian Clinical Practice Guidelines for Schizophrenia.

Dr. Honer has received the Young Investigator Award and the Heinz Lehmann Award from the Canadian College of Neuropsychopharmacology and a Scientist Award from the Canadian Institutes of Health Research. He is also the recipient of a 2011 Award for Excellence in Mentoring Early Career Faculty from the UBC Faculty of Medicine.

In his role of Director, Dr. Honer will provide leadership in teaching and research, and in promoting and improving patient care and clinical service delivery, working in partnership with affiliated Health Authorities across B.C.

Athanasios Zis, MD. FRCPC  (January 2011 - June 2011)

Allan H. Young, MB, ChB, MPhil, PhD, FRCPsych, FRCPC (January 2007 - December 2010)

Dr. Allan Young

Professor Allan H Young, Director of the UBC Institute of Mental Health, Leading Edge Endowment Fund Chair in Depression Research and Professor in the UBC Department of Psychiatry.

Dr. Young received his Medical Degree from the University of Edinburgh. He subsequently underwent postgraduate training in the University of Edinburgh and the University of Oxford, receiving his MRC Psych in 1988 and FRCPsych in 2003. Since 1999, he has been Professor of General Psychiatry and Director of Psychiatry, School of Neurology, Neurobiology and Psychiatry at the University of Newcastle upon Tyne, as well as an Honorary Consultant Psychiatrist.

Dr. Young’s research has focused on the causes and treatment of severe psychiatric disorders, particularly mood disorders. His research examines the causes and treatment of severe mood disorders and he is particularly interested in the procedures and protocols of proof-of-concept studies for novel drug treatments in psychiatry.

 

Anthony G. Phillips, PhD, FRSC (  May 2005 - 2008)

Anthony G. Phillips

Dr. Anthony G. Phillips is a world-renowned expert in brain function and behaviour. He is the Scientific Director of the CIHR Institute of Neurosciences, Mental Health and Addiction, the Founding Director of the UBC Institute of Mental Health, a Professor in the Department of Psychiatry and a senior investigator with the University of British Columbia/Vancouver Coastal Health Brain Research Centre. He is a former Head of the Department of Psychology at the University of British Columbia.

Dr. Phillips earned his Bachelor of Arts, Master of Arts and PhD in Psychology from the University of Western Ontario. His research focuses on the neurobiology of motivation, drug addiction and mental illness, with a specific emphasis on clinical implications. He has published over 300 peer-reviewed papers, and is a Fellow of the Royal Society of Canada.

Dr. Phillips is a founder of QLT, one of Canada’s leading biotechnology companies, and is currently a director of Allon Therapeutics Inc. He serves as a Councillor for the Society for Neuroscience and is the Vice-President of the Collegium Internationale Neuro-Psychopharmacologicum (CINP). He is also actively involved in numerous other national and international neuroscience programs.

Dr. Phillips has received numerous awards for his research including a Steacie Fellowship from NSERC; and most recently, the Heinz Lehmann Award from the Canadian College of Neuropsychopharmacology in March 2009. He maintains a very active and productive laboratory in systems neuroscience.

 

 

 

Dear Colleagues,

I am pleased to announce that the Institute of Mental Health (IMH) has established the Marshall Scholars and Fellows Program in Mental Health to support training of young investigators in translational research in order to create research capacity in mental health.

The idea of investing in promising young scholars who will contribute to advancing understanding and treatment of psychiatric disorders was inspired by Sunny and Stewart Marshall’s vision, and therefore, we would like to take this opportunity to thank Sunny and Stewart for their support, dedication, and commitment to advance mental health research.

The Institute of Mental Health in partnership with the Department of Psychiatry is now inviting applications from qualified candidates for Scholar and Fellow awards which will be supported by the Marshall Scholars and Fellows Program in Mental Health. The program will fund stipends of $75,000 per year for each Fellow and $25,000 per year for each Scholar, for up to two years. The program is expected to fund up to 4 fellows and 15 scholars each year.

Please find the attached application form, along with further information and guidelines. The complete application package must be submitted electronically to psychiatry.headasst@ubc.ca before the deadline (March 31, 2019 no later than 4:30 pm, Pacific Time).  We encourage all qualified applicants to apply and I would like to ask that this information be circulated widely

If you have questions or require further information regarding these awards, please contact Vicky Yau, Director, Administration, at vicky.yau@ubc.ca.

Sincerely,

 

Dr. Lakshmi N. Yatham, MBBS, FRCPC, MRCPsych (UK), MBA (Exec)
Professor and Head, UBC Department of Psychiatry
Director, Institute of Mental Health, UBC
Regional Head and Program Medical Director, VCH/PHC

Chair – Glenn Wong

Glenn Wong is founder of the consulting company, Catalyst Solutions Ltd. that focuses on corporate strategy and governance. He received his B.Comm from the University of British Columbia and is a certified corporate director.

Glenn has served as President/CEO of several companies including Electronic Arts Canada, Rogers Cable TV BC and BC Hot House – a growers’ cooperative. Previous to that, Glenn worked for Procter & Gamble and Nabob Foods, rising to Vice President of Marketing.

In addition to LIFT Philanthropy, Glenn has extensive community involvement which includes serving as a board member of the Canadian Media Fund and Coast Capital Savings Credit Union.  His past service includes being Vice Chair of the Vancouver Police Board as well as serving on the boards of the BC Cancer Foundation, EComm 911, S.U.C.C.E.S.S. (immigrant social services), ICBC and UBC’s Sauder School of Business Faculty Advisory Board.

Mr. Wong is a two-time winner of the American Marketing Association BC Chapter Marketer of the Year Award.

Director – Dr. Lakshmi N. Yatham

Dr. Yatham is a professor and Department Head in the Department of Psychiatry, Director of the UBC Institute of Mental Health, and Regional Head of Psychiatry and Regional Program Medical Director for Mental Health and Addictions at Vancouver Coastal Health and Providence Health Care. He has an Executive MBA from the Sauder School of Business and a wealth of leadership experience in academic, healthcare and professional organizations. He has held leadership positions such as the President for the International Society for Bipolar Disorders, the Secretary for the World Federation of Societies of Biological Psychiatry (WFSBP), and is now the President-Elect of the WFSBP.

Dr. Yatham’s major areas of research interest include neurobiology and treatment of bipolar disorder. His research has contributed to several advances in understanding and treatment of bipolar disorder including disease progression, importance of early intervention in arresting disease progression, and development of new treatments. He has published about 300 peer reviewed papers and is one of the few most highly cited researchers in psychiatry/psychology in the world. He is on the editorial boards of a number of international journals and a Scientific Advisory Board member of the International Bipolar Foundation and Harvard’s Dauten Family Center for Bipolar Studies. Dr. Yatham has been the lead for publication of the CANMAT bipolar guidelines which are widely cited and adopted for use by clinicians from around the world. He has received numerous national and international awards for his contributions to research and leadership in the field of bipolar disorders.

 

Dean, Faculty of Medicine – Dr. Dermot Kelleher

Dr. Kelleher joined UBC in 2015 as Dean of the Faculty of Medicine. Prior to his appointment at UBC, Dr. Kelleher served as Vice-President Health and Dean of the Faculty of Medicine at Imperial College London, where he also held a concurrent appointment as Dean of the Lee Kong Chian Medical School in Singapore until 2014. Dr. Kelleher has also served as Head of the School of Medicine and Vice Provost for Medical Affairs at Trinity College, Dublin.

Dr. Kelleher graduated from medicine from Trinity College Dublin in 1978, going on to specialize in gastroenterology. Author of 300 publications and 14 patents, Dr. Kelleher’s research examines the immune response to many of the leading causes of gastrointestinal infectious disease worldwide. Over the years he has received many prestigious awards including a Fogarty Scholarship at the University of California San Diego, Wellcome Senior Fellow in Clinical Science, and most recently the Conway Medal from the Royal Academy of Medicine in Ireland.

With a strong commitment to innovation and collaboration, Dr. Kelleher has worked to found several companies supporting both translational developments in biomedical science and fostering collaboration in biomedical research in both Dublin and London. He also served as President of the Federation of European Academies of Medicine until moving to British Columbia.

 

Members at large

Leigh Sauder

As well as founding her Travel Business at the age of 23, Leigh has been actively involved with her family’s Wood Manufacturing and Distribution Business, serving as a Board member of Sauder Industries Ltd. since 1999.

While raising her four children, Leigh became passionate about Social Justice Issues. It became clear to Leigh that her own experience of being raised on the West Side of Vancouver differed greatly from environments of less privilege. Her interest extended beyond the comfort of her community when in 2006 Leigh journeyed to Kenya with her oldest daughter to live and work alongside the Kenyan people living in abject poverty. This work sparked a long-term involvement with ACCESS (the African Canadian Continuing Education Society), and in 2007 Leigh accepted a position on the Board where she has remained very involved for the past many years. Helping Kenyans lift themselves out of poverty through education is the mission and focus of ACCES, as well as building capacity for the Kenyan Alumni to create and run a Social Enterprise.

Leigh is a Founding Member of CDL-West at UBC. CDL is a seed-stage program for massively scalable science-based companies. Leigh’s ongoing commitment to the local community includes her recent appointment as a Board Member of the Institute for Mental Health at UBC.

Darren Entwhistle

Darren Entwistle joined TELUS in 2000 as President and CEO, becoming the longest-serving CEO amongst incumbent telecommunication companies worldwide. Under Darren’s leadership, TELUS has evolved from a regional telephone company serving Western Canada into a national data and wireless leader.

Darren has a Bachelor of Economics (Honours) degree from Concordia University, an MBA in Finance from McGill University and a diploma in Network Engineering from the University of Toronto. He has received honorary Doctorates of Law from McGill University, Concordia University, the University of Alberta and the University of Victoria. Darren also holds an honorary Bachelor in Business Administration from the Northern Alberta Institute of Technology and is an Honorary Fellow of The Royal Conservatory in Toronto.

Darren currently serves on the boards of the Gairdner Foundation and the Canadian Board Diversity Council, and is a founding member of the 30% Club Canada. Darren’s past directorships include George Weston Ltd., the Business Council of Canada, TD Bank Financial Group, McGill University Board of Governors and Bell Cablemedia Plc in the United Kingdom.

Darren received the Queen Elizabeth II Golden Jubilee Medal (2003) and the Queen Elizabeth II Diamond Jubilee Medal (2012) in recognition as a Canadian business leader who has made exemplary contributions to the community and to Canada as a whole.

Sunny Marshall

Sunny is one of ten children born and raised in East Vancouver in an area called “The Project”, a housing development reserved for WWII veterans.

After finishing high school she worked at various jobs including a dozen years in the investment industry.  She and her husband, Stewart, foster parented a number of children and adopted two sons, Adam and Charlie.  Sunny has always had a soft spot for the welfare of the disadvantaged and a particular interest in mental health.  She is delighted to be a part of this exciting project because of its focus on research and the causes of mental illness, which will hopefully one day lead to more effective treatment.

 

 

 

Stewart Marshall

Stewart is a retired executive from the financial services industry, where he worked for 30 years.  He holds a Bachelor of Commerce degree in Finance from the University of British Columbia, 1982.  In 1987 he earned his Chartered Financial Analyst designation.

From 1990 to 2013 Stewart was a partner of Phillips, Hager & North Investment Management (PH&N), where he specialized in investment analysis and portfolio management.  His clients included corporate, union and university pension & endowment plans and private clients.  Stewart was very involved in recruiting and building the PH&N team.  He was a regular presenter to small institutional committees and at large public forums.   From 1982 to 1990 Stewart worked for Dominion Securities.

Stewart is on the board of Golftec Canada, as well as being a long-time director of the Terminal City Club.  He is a former director of Phillips, Hager & North, a Past President & Director of The Vancouver Society of Financial Analysts and past Director of Canadian Counsel of Financial Analysts.

Stewart and his wife, Sunny, have two sons and live in West Vancouver.

Stewart is a member of Seymour Golf & Country Club, Evergreen Squash Club and Terminal City Club.   He spends his a lot if time golfing, skiing, cycling, kitesurfing and playing squash.

Ruth James, BEd., MEd,

I was employed as a public school teacher in District 38, Richmond, B.C. for over 20 years.

I taught at the primary and intermediate levels and finally at an innovative interdisciplinary programme for 120 students wanting to return to school to complete academic qualifications for high school completion. The programme was called “Combined Studies”. 80% of the students were boys and there was a high ratio of ADHD students as well as students born in November and December. My colleagues and I were invited to consult for 'New Visions for Public Schools' in Harlem and the Bronx, USA.

 

In 1991 I became a director of The African Children’s Book Box Society, a literacy project in East Africa. Every year I volunteer for 4 to 6 weeks in poverty stricken classrooms.

This year, my first children’s story is being published in both Kiswahili and English. 'Paseka, a little Elephant, Brave’ explores the plight of being an orphan, developing resilience and searching for support in a new community. Two members of my family have been formally diagnosed with ADHD. This has lead to a life long quest to learn and promote understanding of the condition and also to provide meaningful support.

Anne – Marie Kains Bio to come

Yasmin Jetha

As Vice President, Community Services, Yasmin Jetha plays a pivotal role in the planning and transformative changes necessary to achieve VCH's vision for a new, integrated model of primary and community care. She oversees six Regional Program Leadership Teams - Primary Care; Home Health; End of Life; Mental Health & Substance Use; Residential Care; and Medicine.

Yasmin brings a wealth of leadership experience in clinical operations and the implementation of complex system changes to the position. Along with a Masters in both Social Work and Health Administration from the University of British Columbia, Yasmin brings more than two decades of experience in senior health care roles with VCH, Fraser Health and the Provincial Health Services Authority. Most recently, she was the Regional Program Director of Palliative/End of Life Care and the Director of Home, Community and Palliative Care within Vancouver Community.  Prior to this, she was the VCH Regional Executive Director for Mental Health and Substance Use as well as the Director of Mental Health and Addictions for the VCH's Richmond community of care.

She was nominated in 2015 for a BC Premier's Award for her work on a multi-system response to addressing the needs of individuals dealing with mental health and substance use issues, and is actively involved in bringing external stakeholders together to collaborate on transforming the way health care services are provided in a community setting. Yasmin was also recognized by the VCH Board and Senior Executive Team in 2011 with a People First Award for "Leadership by example with vision, dynamic, innovation and client-centered care". She joined the VCH Senior Executive Team in September 2017.

Dr. Anson Koo

Dr. Anson Koo is the Program Medical Director, Regional Department Head, and Head of Academic Psychiatry for the Mental Health and Substance Use Program in the Fraser Health Authority (FHA). He was previously the Psychiatry Head of Department at the Royal Columbian Hospital, and the Division Head for Adult Acute and Community Psychiatry Programs in FHA. He is a Clinical Associate Professor in the UBC Department of Psychiatry.  His clinical practice is in Adult Inpatient Psychiatry at the Royal Columbian Hospital.  Dr. Koo is very involved in undergraduate and postgraduate medical education, both as an educator and administrator.  He has overseen the establishment of a psychiatry residency program based in Fraser Health, and is a member of the UBC CaRMS resident selection committee.  As Academic Psychiatry Lead for FHA, he has developed a regional network of teaching sites and academic faculty, and expanded psychiatric medical education across the Fraser Health Authority.  He serves on the UBC psychiatry undergraduate education committee as a Discipline Specific Site Leader.  In his regional medical administrative roles, Dr. Koo has provided strategic and operational medical leadership during a period of significant service expansion within Fraser Health in both the mental health and addiction medicine programs. His particular areas of interest include medical education, health resource equity, leadership development, and innovation in service integration across the acute and community continuum of care.

Dr. Caroline Gosselin

Caroline Gosselin is Clinical Professor and Geriatric Division member of the UBC Department of Psychiatry and is in active geriatric psychiatry practice at the Vancouver General Hospital. She is a Founding Member of the RCPSC Geriatric Psychiatry subspecialty and was an examiner  for the RCPSC Psychiatry Examination Board for a decade and Chief Examiner from 2014 to 2018. She is a co-founder of the Canadian ECT Survey (CANECTS/ECANEC I), Co-Chair of the Canadian ECT Standards (CANECTS/ECANEC II) and is an award-winning educator.

 

Dr. Lakshmi N. Yatham

Dr. Yatham is a professor and Department Head in the Department of Psychiatry, Director of the UBC Institute of Mental Health, and Regional Head of Psychiatry and Regional Program Medical Director for Mental Health and Addictions at Vancouver Coastal Health and Providence Health Care. He has an Executive MBA from the Sauder School of Business and a wealth of leadership experience in academic, healthcare and professional organizations. He has held leadership positions such as the President for the International Society for Bipolar Disorders, the Secretary for the World Federation of Societies of Biological Psychiatry (WFSBP), and is now the President-Elect of the WFSBP.

Dr. Yatham’s major areas of research interest include neurobiology and treatment of bipolar disorder. His research has contributed to several advances in understanding and treatment of bipolar disorder including disease progression, importance of early intervention in arresting disease progression, and development of new treatments. He has published about 300 peer reviewed papers and is one of the few most highly cited researchers in psychiatry/psychology in the world. He is on the editorial boards of a number of international journals and a Scientific Advisory Board member of the International Bipolar Foundation and Harvard’s Dauten Family Center for Bipolar Studies. Dr. Yatham has been the lead for publication of the CANMAT bipolar guidelines which are widely cited and adopted for use by clinicians from around the world. He has received numerous national and international awards for his contributions to research and leadership in the field of bipolar disorders.

Dr. Jehannine Austin

Jehannine is a Professor in Psychiatry & Medical Genetics at UBC, where she holds the Canada Research Chair in Translational Psychiatric Genomics. She is executive director of PHSA's BC Mental Health and Addictions Research Institute. Her research work involves studying the impact of genetic counseling for people with psychiatric disorders and their families. She founded the worlds first specialist psychiatric genetic counseling service that has won an award for its impact on patient outcomes, and in addition to peer-reviewed publications, has written a book and won awards for teaching, innovation, leadership, and research. She is a member of the College of the Royal Society of Canada, and a Fellow of the Canadian Academy of Health Sciences.

Dr. Liisa Galea

Liisa Galea is a Professor in the Department of Psychology, a member of the Centre for Brain Health, Director of the Graduate Program in Neuroscience, and a Scientific Advisor at Women’s Health Research Institute at the University of British Columbia. My research investigates how sex hormones influence brain health and disease in both females and males. The main goal of my research is to improve brain health for women and men by examining the influence of sex and sex hormones on normal and diseased brain states such as depression and Alzheimer’s disease.

 

 

 

Dr. Trevor Hurwitz

Dr. Hurwitz completed his medical degree in Pretoria, South Africa followed by an internship in Johannesburg and a senior housemanship in Cape Town.  He continued his studies in London, England and obtained certification in Internal Medicine.  He completed a residency in Psychiatry at the University of British Columbia in 1980 and a residency in Neurology at Boston University in 1982.

Currently Dr. Hurwitz is a Clinical Professor in the Department of Psychiatry at the University of British Columbia.  He is the Director of the B.C. Neuropsychiatry Program and Chief-of-Service of West-1 at UBC Hospital, Vancouver.  Dr. Hurwitz has a joint appointment in the Department of Medicine, Division of Neurology and practices as a clinical neurologist in addition to his primary commitment to inpatient and outpatient Neuropsychiatry.

Dr. Hurwitz’s work is mostly devoted to clinical practice, teaching and the promotion of the discipline of Neuropsychiatry with some research interests in the field of Neuropsychiatry.

Dr. Michael Krause

Dr. Michael Krausz is originally from Hamburg, Germany, where he was trained at the University Medical Center Hamburg-Eppendorf. Following his training, he worked in three different clinical and research positions in general psychiatry.

In the mid 1990s, he became a founding director of the Centre of Interdisciplinary Addiction Research at the University of Hamburg and retained directorship at the centre until 2004. As a founding director, he was also responsible for the German Heroin Trial, the European Cocaine Project, and several other notable addiction-related trials.
He was also Editor-In-Chief of two well-established scientific journals; Suchttherapie and European Addiction Research respectively. He has also published more than 300 scientific papers to date. Dr. Krausz is also a founding member of the International Society of Addiction Medicine (ISAM) and is currently serving on the boards of the Section of Addiction and the Section of Public Policy for the World Psychiatric Association.

Michael relocated permanently to the Vancouver area in 2007 and became a professor of psychiatry and the University of British Columbia (UBC) as well as the LEEF Chair in Addiction Research at the Institute of Mental Health at UBC.

Dr. Raymond Lam

Dr. Raymond W. Lam is Professor and Associate Head for Research & International Affairs , and Residency Director of Scholarly Activity and Research Track, in the Department of Psychiatry, University of British Columbia (UBC) and Director of the Mood Disorders Centre at the Djavad Mowafaghian Centre for Brain Health in Vancouver. His research examines clinical and neurobiological factors in seasonal, treatment-resistant and workplace depression, clinical trials and guidelines, and eMentalHealth. Dr. Lam is also a lead investigator for the Canadian Biomarker Integration Network in Depression (CAN-BIND). His research is supported by many agencies including the Canadian Institutes of Health Research and by investigator-initiated industry research grants.

 

 

Co-Chair Dr. Robert Post

Throughout his career, including 35 years at the NIMH, and 20 of those as Chief of the Biological Psychiatry Branch, Dr. Post has focused on bettering the understanding and treatment of refractory unipolar and bipolar illness. He founded the International Stanley Foundation Bipolar Network (now the Bipolar Collaborative Network). Currently, he is in private practice and attempting to address childhood-onset bipolar illness.

Dr. Post helped pioneer the use of the anticonvulsant carbamazepine as treatment for lithium-resistant patients with bipolar disorder. Prior to leaving the NIMH, he and his group were exploring nonconvulsive brain stimulation with repetitive transcranial magnetic stimulation (rTMS) for treatment of unipolar and bipolar depression. Animal studies have enabled him to re-conceptualize affective illness recurrence and evolution at the level of cyclic alterations in gene expression. These views emphasize the importance of early, long-term treatment of mood disorders to prevent progressively increasing vulnerability to episode recurrence, cycle acceleration and treatment resistance.

 

Co-Chair Dr. Ayal Schaffer

Ayal Schaffer (MD, FRCPC) is Head of the Mood and Anxiety Disorders Program, andDeputy Psychiatrist-in-Chief, at Sunnybrook Health Sciences Centre, Toronto, Canada.He is an Associate Professor in the Department of Psychiatry, University of Toronto, VicePresident Education for the International Society for Bipolar Disorders, and on the Boardof the Canadian Network for Mood and Anxiety Treatments (CANMAT).

Dr. Schaffer’s research interests involve the management of bipolar disorder andtreatment-resistant depression, understanding suicide risk and prevention, and examiningpopulation-health trends in the treatment of mental illness. Dr. Schaffer has been aprincipal or co-investigator of studies funded by the Ontario Mental Health Foundation,Canadian Institute of Health Research, National Institute of Mental Health (U.S.),Ontario Ministry of Health and Long-Term Care, PSI Foundation, American Foundationfor Suicide Prevention, the Stanley Medical Research Institute, and others.

Dr. Schaffer co-authored the CANMAT / ISBD Guidelines for the Management ofBipolar Disorder as well as co-leading the CANMAT Task Force on Comorbidity inMood Disorders. He recently chaired the International Society for Bipolar DisordersTask Force on Suicide. Dr. Schaffer has an outpatient and inpatient practice atSunnybrook, where he is also chair of the Department of Psychiatry QualityImprovement Committee. He is actively involved in teaching at the undergraduate,postgraduate, and continuing educations levels.

Dr. Stephanie Ameis

Dr. Stephanie Ameis is the inaugural O’Brien Scholar within the Child and Youth Mental Health Collaborative at CAMH and Sick Kids and a clinician-scientist within the Campbell Family Mental Health Research Institute at CAMH and the Program in Brain and Mental Health at The Hospital for Sick Children in Toronto She is Assistant Professor in the Department of Psychiatry, Faculty of Medicine at the University of Toronto.

Dr. Ameis’ clinical work focuses on providing evidence-based assessment and care for children, youth and emerging adults with autism spectrum disorders. The main goals of her research are to: (i) use brain imaging to learn how variation in brain circuit structure and function relates to behaviour as a means to develop new targets for treatment and (ii) use brain imaging to understand how existing and novel (i.e., medications, behavioural therapies, brain stimulation) interventions/treatments work.

Dr. Ana Cristina Andreazza

Dr. Andreazza is an Associate Professor in the Departments of Pharmacology & Toxicology and Psychiatry and holds a holding Tier II Canada Research Chair in Molecular Pharmacology of Mood Disorders. She is cross-appointed as a collaborator Scientist at the Centre for Addiction and Mental Health. Dr. Andreazza is an Advisor for the Dauten Family Center for Bipolar Treatment Innovation at Massachusetts General Hospital, a consultant for the Bipolar Biobank at Mayo Clinic and as a member of the Board of Directors from the International Society of Bipolar Disorder.

Dr. Andreazza received PhD in Biochemistry from the Federal University of Rio Grande do Sul, RS, Brazil. She has published over 140 research articles with an h-index factor of 45. She is the recipient of several prestigious research awards, including the 2018 Canada Top 40 Under 40 and has received funding from the Brain and Behavior Foundation (NARSAD), the Canadian Institutes for Health Research, the Ontario Mental Health Foundation and the Ontario Ministry of Research and Innovation. Her research focuses on the understanding of the role of redox modulations and mitochondrial dysfunction in mental illness, especially in mood disorders.

Dr. Andreazza research focuses on the understanding of the role of mitochondrial function in mental illness, especially in mood disorders. As neurons depend on mitochondrial function, dysfunctional mitochondrial during neurodevelopment is expected to impact neurotransmission with potentially crucial implications for mood disorders. Currently, Dr. Andreazza is evaluating the impact of mitochondrial dysfunction on neurotransmission using 3D brain organoids generated from induced pluripotent stem cells from patients with bipolar disorder and/or mitochondrial disease.

Dr. Paul Arnold

Dr. Arnold, MD, PhD is a the inaugural Director of the Mathison Centre for Mental Health & Education and the Alberta Innovates Translational Health Chair in Child and Youth Mental Health at the University of Calgary. He is an Professor with the Departments of Psychiatry, Cumming School of Medicine, University of Calgary and a child and adolescent psychiatrist practicing at Alberta Children’s Hospital. His research focuses on how genetic and environmental risk factors interact to influence the development of child onset neuropsychiatric disorders.

 

Dr. Rosemary C. Bagot

Dr Bagot earned her BSc (Hons) in Psychology at the University of New South Wales, Sydney, Australia. Her Ph.D. in Neuroscience at McGill University, identified synaptic and transcriptional mechanisms by which early life adversity regulates life-long differences in glutamatergic transmission in hippocampus. During her postdoctoral research at the Icahn School of Medicine at Mount Sinai in New York, USA she established pathway-specific roles of glutamatergic inputs to the nucleus accumbens in stress regulation of emotional behaviors and identified key gene networks underpinning the functional stress-induced adaptations in these circuits. In 2016, she joined the Department of Psychology at McGill University as an Assistant Professor in Behavioural Neuroscience. She is a William Dawson Scholar, an Associate Member of the Department of Psychiatry at McGill University, a Primary Investigator at the Ludmer Centre for Neuroinformatics and Mental Health and a member of the Concordia Centre for Studies in Behavioral Neurobiology. Research in the Bagot lab uses a multi-disciplinary approach integrating in vitro electrophysiology, in vivo optogenetics, in vivo calcium imaging and next-generation sequencing in robust mouse behavioural models to gain insight into neural circuit mechanisms of depression. Specific projects focus on identifying pre-existing mechanisms of individual differences in stress susceptibility and circuit mechanisms of depression-relevant cognitive phenotypes.

Dr. Glen Baker

Glen Baker is currently Distinguished University Professor Emeritus in the Department of Psychiatry at the University of Alberta. He did his undergraduate degree in Pharmacy, an MSc in medicinal chemistry and a PhD in Biological Psychiatry at the University of Saskatchewan.  This was followed by  postdoctoral research (with a fellowship from the MRC of Canada) at the MRC Neuropharmacology Unit at the University of Birmingham, England before joining the Department of Psychiatry at the University of Alberta in 1977. He is a former Chair of the Department of Psychiatry and a founding member of the Neurochemical Research Unit at that university, a past president of the Canadian College of Neuropsychopharmacology (CCNP), a former Tier I Canada Research Chair and a former Associate Vice-President of Research for the University of Alberta.

Dr. Baker is a Fellow of the Canadian Academy of Health Sciences and was a University of Alberta Distinguished University Professor. He was Series Co-Editor for the book series Neuromethods for 20 years and has served on the editorial boards of several journals.   He has published over 375 peer-reviewed papers, 425 abstracts and numerous editorials, book chapters, invited review articles and abstracts and was co-holder of 3 patents. He has been well funded for many years by various national and provincial granting agencies and has had numerous research collaborators locally, nationally and internationally.

His main research interests are mechanisms of action and metabolism of psychiatric drugs used in treatment of mood and anxiety disorders and schizophrenia; biomarkers in psychiatric and neurological disorders; analytical neurochemistry; and drug development, with a focus on neuroprotection.   Dr Baker has supervised or cosupervised over 40 graduate students and 23 postdoctoral fellows as well as numerous summer students and psychiatry residents who have done research projects with him, and he has served on supervisory or examination committees for over 160 graduate students other than his own.  He has served on many grant panels and advisory boards as well as organizing committees for several national and international conferences in neurochemistry and neuropsychopharmacology.

His awards include the College Medal and Innovations in Neuropsychopharmacology Research Award of the CCNP, a McCalla Research Professorship, a Killam Professorship, a University of Alberta Killam Research Award for Excellence in Mentoring, a REACH Team Award from Capital Health and an Alumni Award of Achievement from the University of Saskatchewan.  Dr. Baker was one of the alumni to receive the 100 Alumni of Influence Award during the University of Saskatchewan Centenary (2007) and in 2014 was the recipient of a Centennial Alumni of Influence Award from the College of Pharmacy and Nutrition at the University of Saskatchewan.  In 2015 he received the Medal of Honor of the Alberta Medical Association and in 2018 the Department of Psychiatry Resident Research Award for supervision of residents.

Dr Benjamin I. Goldstein

Dr. Goldstein is a child-adolescent psychiatrist and Professor of Psychiatry, Pharmacology, and Psychological Clinical Science at the University of Toronto, as well as Adjunct Professor of Psychiatry at the University of Pittsburgh.  He is the Director of the Centre for Youth Bipolar Disorder and Director of Research in the Department of Psychiatry at Sunnybrook Health Sciences Centre, and a Senior Scientist at Sunnybrook Research Institute. Dr. Goldstein’s efforts focus on teenagers with, or at familial risk for, bipolar disorder. His team seeks to identify clinically relevant biomarkers, and innovative prevention and treatment strategies that focus simultaneously on physical and mental health. Dr. Goldstein has authored over 150 scientific articles, and has received international awards for his research. His research is currently funded by grants from Brain Canada, CIHR, the Heart and Stroke Foundation, and the Ontario Ministry of Research, Innovation and Science. An active educator, Dr. Goldstein serves as Director of the Clinician Scientist Program in the University of Toronto’s Department of Psychiatry.

Dr. Paul Kurdyak

Dr. Kurdyak completed his medical degree, psychiatry residency training, and PhD in clinical epidemiology at the University of Toronto. He is a staff psychiatrist at the Centre for Addiction and Mental Health, and is the Director of the Health Outcomes and Performance Evaluation (HOPE) Research Unit within the Social and Epidemiological Research Program. Dr. Kurdyak is also the Lead of the Mental Health and Addictions Research Program at the Institute for Clinical Evaluative Science (ICES). Dr. Kurdyak provides oversight on the evaluation of complex mental health interventions and provincial strategies through his role as Director of Health Outcomes for the Medical Psychiatry Alliance and as a consultant to the Ministry of Health and Long-Term care and Health Quality Ontario.

 

 

 

Dr. Alex McGirr

Alexander McGirr is an Assistant Professor in Psychiatry at the University of Calgary, where he holds the Campus Alberta Innovates Chair in Neurostimulation. He completed his residency training in psychiatry and his PhD in neuroscience at the University of British Columbia. His research program involves using non-invasive neurostimulation modalities to probe brain function and as a treatment for Major Depressive Disorder and Bipolar Disorders. He simultaneously runs a pre-clinical imaging program using mouse models to understand pathological changes that occur in chronic stress, and other risk factors for mood disorders in humans.

 

 

 

Dr Michael Meaney

Dr Meaney is a leading researcher and laboratory director at the Douglas Mental Health University Institute, an Adjunct Senior Investigator at the Singapore Institute for Clinical Sciences, a James McGill Professor in the departments of Psychiatry and Neurology & Neurosurgery at McGill University, and the Director of the Program for the Study of Behaviour, Genes & Environment at McGill University.

Dr Meaney’s laboratory focuses on epigenetics, the biological basis by which environmental factors produce an enduring effect on genomic structures and function, and the resulting phenotype variations, including mental illnesses and learning disabilities. These studies focus on epigenetic modifications to the genome that regulate gene activity, altering or switching them ‘on and off’. This work involves both basic science and translational research models, ranging from studies of molecular mechanisms to brain-development and -function in humans.  Dr Meaney is also the director of the Maternal Adversity, Vulnerability & Neurodevelopment (MAVAN) project, a Montreal-based longitudinal study of paediatric epigenetics, and a primary investigator in Singapore’s largest birth cohort study, Growing Up in Singapore Towards healthy Outcomes (GUSTO).

Dr. Andrew A. Nierenberg

Andrew A. Nierenberg, M.D. graduated from the Albert Einstein College of Medicine of Yeshiva University, Bronx, NY. After completing his residency in psychiatry at New York University/Bellevue Hospital, he studied clinical epidemiology at Yale University as a Robert Wood Johnson Clinical Scholar. Dr. Nierenberg then joined the faculty at Harvard Medical School, first at McLean Hospital in Belmont, Massachusetts and then at Massachusetts General Hospital (MGH), where he holds his current positions. He is also Honorary Professor in the School of Medicine, Faculty of Health at Deakin University, Geelong Australia.

 

Dr. Nierenberg has published over 475 papers and has been listed in The Best Doctors in America for the treatment of mood and anxiety disorders in every edition since 1994. In 2000, he was awarded the Gerald L. Klerman Young Investigator Award and in 2014 the Gerald L. Klerman Senior Investigator Award by the Depression Bipolar Support Alliance. In 2013, Dr. Nierenberg was awarded the prestigious Brain and Behavior Research Foundation Colvin Prize for outstanding achievement in mood disorders research. In 2014, he was awarded the Mentorship Award for Exceptional Mentorship in the Research Arena at MGH. In 2014, 2015, 2016, and 2017, he was listed among the World’s Most Influential Scientific Minds by Clarivate Analytics in recognition of ranking among the top 1% of researchers for most cited papers in psychiatry worldwide with over 25,000 citations and an h-factor of 78.

Dr. Nierenberg’s primary interest is innovative treatments for bipolar disorder. He lectures extensively, both nationally and internationally, teaches, supervises, maintains an active clinical practice, consults to industry, and conducts clinical trials funded by federal, foundation, industry, and philanthropic sources.. Dr. Nierenberg is the deputy editor of Depression and Anxiety and editor of Psychiatric Annals. He is a member of the editorial boards of over 15 journals including the Journal of Clinical Psychiatry, Journal of Clinical Psychopharmacology, Journal of Affective Disorders, Australian New Zealand Journal of Psychiatry, and Bipolar Disorders and serves as a peer reviewer for over 35 psychiatric journals.

Dr. Lena K. Palaniyappan

Dr. Lena Palaniyappan is an Associate Professor at the Departments of Psychiatry and Medical Biophysics at the Western University, and Director of the Prevention and Early Intervention in Psychoses Programme (PEPP), London, Ontario. He completed his MD at Stanley Medical College, Chennai, India followed by PhD in Translational Neuroimaging at the University of Nottingham, UK. His research team Neuroimaging in Mental Illnesses is based at the Robarts Research Institute, Western University.

 

 

 

Dr. Scott B. Patten

Dr. Patten obtained a medical doctorate (MD) from the University of Alberta (Edmonton, Canada) in 1986 and subsequently a specialist certification (FRCPC) in Psychiatry in 1991. He completed a PhD in epidemiology at the University of Calgary in 1994. Currently, he is a Professor in the Cumming School of Medicine at the University of Calgary, where he teaches MDCH740, Advanced Epidemiology. His research is concerned with the descriptive epidemiology of common mental disorders (especially depression) and medical-psychiatric comorbidity in the Canadian population. He currently holds the Cutherbertson and Fischer Chair in Pediatric Mental Health at the University of Calgary and is the Editor Emeritus of the Canadian Journal of Psychiatry.

 

Dr. Soham Rej MD, MSc

Soham Rej completed his medical school (2009) and psychiatry residency at McGill (2014), followed by a geriatric psychiatry clinical and research fellowship at the University of Toronto (2017). He is an assistant professor at McGill. He started working as a Geriatric Psychiatrist and Junior Clinician-Scientist at the Jewish General Hospital/Lady Davis in Feb 2017.

Soham's research had primarily examined medication-related physical comorbidity late-life mood disorders, with a focus on lithium and the kidney. Since 2016, he has a secondary interest examining clinical trials of mind-body interventions (e.g. mindfulness) in the treatment of late-life mood, anxiety, and cognitive disorders. He has 75 peer-reviewed publications. He is grateful to the Fonds de Recherche en Quebec Sante (FRQS) Clinician-Scientist program, Canadian Institutes of Health Research (CIHR), and other agencies for their continued grant support.

 

 

Mark Sinyor

Dr. Mark Sinyor is a Psychiatrist at Sunnybrook Health Sciences Centre, an Assistant Professor in the Department of Psychiatry, Faculty of Medicine at the University of Toronto and an Associate Scientist at the Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute.  His clinical focus is on treatment of mood and anxiety disorders and he coordinates Sunnybrook’s Mood Disorders Clinic.  He is the founder of PROGRESS (the Program of Research and Education to Stop Suicide) at Sunnybrook and sits on the board of directors of the Canadian Association for Suicide Prevention.  His main research focus is on suicide prevention and mental health literacy.  He has more than 40 peer-reviewed publications in high impact factor journals including the British Medical Journal, American Journal of Psychiatry, World Psychiatry and the Canadian Medical Association Journal.  His research has been featured in Time Magazine, the Los Angeles Times, BusinessWeek, CBC’s the National and Radio One, CTV and Global News.  In 2017, he won the Canadian Psychiatric Association’s Early Career Achievement in Psychiatry Award.

 

 

Dr. Philip Tibbo

Dr. Tibbo received his B.Sc. (Hons) from Mount Alison University in Sackville, NB, and his MD from Memorial University of Newfoundland.  He completed his residency in psychiatry at the University of Alberta, and following this joined the staff at the University of Alberta Hospital as a clinician and researcher. He was instrumental in the development of and co-directed both the Bebensee Schizophrenia Research Unit and the Edmonton Early Psychosis Intervention Clinic.

In 2008 Dr. Tibbo was named the first Dr. Paul Janssen Chair in Psychotic Disorders, an endowed research chair, at Dalhousie University in Halifax NS. He is a Professor in the Department of Psychiatry with a cross-appointment in Psychology at Dalhousie University and an Adjunct Professor in Department of Psychiatry at the University of Alberta. He is also Director of the Nova Scotia Early Psychosis Program (NSEPP) and co-director of the Nova Scotia Psychosis Research Unit (NSPRU).

Dr. Tibbo’s publications are primarily in the area of schizophrenia, and his current foci of study include individuals at the early phase of, and individuals at risk for, a psychotic illness. Dr. Tibbo’s areas of research include application of  in vivo brain neuroimaging techniques to study psychosis as well as research interests in co-morbidities in schizophrenia, psychosis genetics, addictions and psychosis, stigma and burden, pathways to care, education, and non-pharmacological treatment options. He is President of the Canadian Consortium for Early Intervention in Psychosis (CCEIP), helping to advance early intervention care at the national level. He is funded by local and national peer reviewed funding agencies and well published in leading journals. Dr Tibbo is a recipient (2015) of the Michael Smith Award from the Schizophrenia Society of Canada for research and leadership in schizophrenia, recipient of the Canadian Alliance on Mental Illness and Mental Health’s Champion of Mental Health Research/Clinician award in 2017 and most recently the recipient of the 2018 Regional Prix d’excellence – Specialist of the Year - Region 5 by the Royal College of Physicians and Surgeons of Canada.

Dr. Simone Vigod

Dr. Simone Vigod is an Associate Professor in the Department of Psychiatry at the University of Toronto, and Lead of the Reproductive Life Stages (RLS) Program at Women’s College Hospital. Her background includes an Honours BSc in Psychology from McGill University (1999), an MD from the University of Toronto, UofT (2003) and psychiatric residency at UofT (FRCPC, 2009). To build her research program, she undertook a Masters of Science in Clinical Epidemiology from the UofT Institute for Health Policy, Management and Evaluation (IHPME) and is now a faculty member therein. Dr. Vigod’s research aims to address disparities in health and health care for individuals with psychiatric disorders, with a specific focus on women across the lifespan and on equity in access to treatment for diverse populations.  She is an Adjunct Scientist at ICES in Toronto, Ontario where she conducts her population-based epidemiological research focused on the health of women with mental illness and their children. In 2018, she obtained the Shirley A. Brown Memorial Chair in Women’s Mental Health Research at Women’s College Research Institute at Women’s College Hospital where she runs the clinical intervention part of her research program that focuses on novel health system interventions to improve access to and uptake of care for women with mental illness.  Her research discoveries have been highlighted at the public level, with significant coverage from international and national media. Dr. Vigod also has a significant presence related to advocacy for quality of care at the provincial and national level that will guide implementation of interventions to improve the quality of mental health care delivery across the country.

Dr. Tak Pan Wong

Dr. Tak Pan Wong is an Associate Professor in the Department of Psychiatry at McGill University and a Researcher at Douglas Mental Health University Institute. He obtained his PhD in Pharmacology in 2001 from McGill University, followed by postdoctoral training at UBC. Since 2006, he has established his research laboratory at Douglas Institute to investigate hippocampal mechanisms that underlie behavioral changes in animal models for psychiatric disorders. He has obtained the Young Investigator award from NARSAD and career awards from FRSQ (Junior I,II and senior).

 

 

 

 

Strategic Plan web badge

 

 

 

IMH Speakers Series Luncheon

In the interest of reaching out and being present in the community, the institute hosts regular luncheon meetings to advance its vision. These intimate meetings of approximately a dozen guests allow community members to learn about the cutting-edge research and work of institute-related faculty members and engage guests in dialogue directly with UBC researchers.

Past Speakers have included:
Dr. William Honer– Schizophrenia
Professor and Head Department of
Psychiatry

Dr. William MacEwan - Schizophrenia
Clinical Associate Professor, Department of Psychiatry

Dr. Anthony Bailey - Autism
Professor, Department of Psychiatry

Dr. Jehannine Austin - Genetics
Associate Professor, Department of Psychiatry

Dr. William Panenka –Neuropsychiatry
Assistant Professor (Partner), Department of Psychiatry

Dr. Evelyn Stewart - Child
Associate Professor, Department of Psychiatry

Coast Capital Savings Fund

To fund research into the causes and treatment of mental illness  in British Columbia.

Coast Capital Golf

 

 

In 2014  Coast Capital Savings Charity Golf Tournament raised $204,373, bringing the total contribution of the annual fundraiser to mental health research in B.C. to more than $1.8 million to date.

The tournament, then  in its 13th year, benefits VGH & UBC Hospital Foundation and is part of Coast Capital Savings' community promise to help build healthy minds by combating depression and other forms of mental illness. Interim Coast Capital Savings president and CEO Don Coulter said the credit union's dedication to addressing mental health challenges faced by British Columbians stems from both a moral and business imperative.

"Many of us know someone who has experienced the silent suffering and stigma often associated with mental illness," Coulter said. "Raising funds for research and treatment is a way for us to translate our caring into action. In addition to the personal toll, mental illness carries significant business and economic costs and we hope the funds raised through the Coast Capital Savings Charity Golf Tournament will help advance the important work being done by researchers in this area."

Monies raised through the Coast Capital Savings Charity Golf Tournament over the years have gone to support mental health research at the University of British Columbia. Dr. William Honer, head of psychiatry at UBC and director of the university's Institute of Mental Health, said public funding is helping researchers make strides in mental health intervention and care.

"The outstanding success of the Coast Capital Savings' Golf Tournament supports clinical research at the UBC and VGH Hospital sites," Dr. Honer says. "The goals are the "three i's": to innovate, incubate, and then integrate advances in the care of mental illness to improve the health of our patients, and create value for the health care system. Carrying this out needs the help of tremendous donor groups like Coast Capital."

Wayne Berg, Coast Capital's chief commercial officer and campaign chair for the 2014 tournament, thanked all the individuals and businesses that participated in this year's event held at Surrey's Northview Golf and Country Club. He commended the organizations that partnered with the credit union as sponsors noting that such strong community response reflects a growing awareness of the importance of mental health funding and support.

"Several businesses have made significant contributions to this fundraising effort since Coast Capital Savings launched the tournament more than a decade ago and it's great to see such leadership from the business community," Berg said. "The success of this year's event owes in large part to the valuable support of platinum sponsors: CRI Canada, Desjardins Card Services, IDC Worldsource, Landcor Data Corp and SEI investments.

Barbara Grantham, president and CEO of VGH & UBC Hospital Foundation, recognized Coast Capital's longstanding support for the Foundation. "Coast Capital Savings has demonstrated exceptional leadership in the community by mobilizing awareness about mental health and supporting path-finding research that will continue to have a positive impact on individuals and families affected by mental illness," Barbara Grantham says. "We are grateful for Coast Capital Savings' longstanding commitment to advancing patient care and research through our hospitals."

Coast Capital Savings has been at the forefront of efforts in the business sector to drive awareness and action on mental health issues both in the workplace and community for many years. As part of the credit union's community investments in this area, Coast Capital recently contributed $432,000 towards Fraser Health's Speak Up campaign, an initiative designed to provide teens and young adults with a voice in the mental health discussion.

Coast Capital Savings is Canada's second largest credit union, owned by its 512,000 members. It has 50 branches in the Metro Vancouver, Fraser Valley and Vancouver Island regions of British Columbia and has exciting plans to grow. Product innovations include Canada's first free chequing account from a full-service financial institution. Coast Capital offers one of Canada's 10 Most Admired Corporate Cultures™ and was named one of 2014's BC Top Employers. It is a member of Canada's Best Managed Companies Platinum Club and an Imagine Canada Caring Company. To learn more, visit www.coastcapitalsavings.com.

 

For more information, contact:

UBC Institute of Mental Health
Department of Psychiatry,
University of British Columbia

Detwiller Pavillon
2255 Wesbrook Mall
Vancouver, BC V6T 2A1

Email: psychiatry.headasst@ubc.ca

Tel : 604 822 7310
Fax : 604 822 0399

The Bell Youth Mental Health IMPACT Project

IMH receives $1M from Bell for online youth mental health outreach and research

Today UBC and Bell announced a $1M gift to establish the Bell Youth Mental Health IMPACT project. This initiative will enable researchers from the University of British Columbia to conduct mental health outreach to youth in need.

The gift was announced today by Mary Deacon, Chair of the Bell Let’s Talk mental health initiative, at a ceremony at UBC Robson Square. Ms. Deacon was joined by Bell President and CEO George Cope, UBC Chancellor Sarah Morgan-Silvester, Faculty of Medicine Vice Dean Ross MacGillivray and Psychiatry Professor Michael Krausz.

The Bell Youth Mental Health IMPACT Project will be led by Dr. Krausz, who is also the UBC-Providence Leading Edge Endowment Fund (LEEF) Chair in Addiction Research, at the Institute of Mental Health, part of UBC’s Faculty of Medicine.

As part of the project, researchers will develop a mental health web portal that provides educational and self-assessment tools, automated feedback, a list of treatment options, advice on obtaining services, and coping techniques. Additional features, such as online consultations through e-mail, chat rooms, video-conferencing, instant messaging and social media tools, will be added in the future based on research into the effectiveness of this outreach model.

“Despite the high prevalence of anxiety and depression, especially among those in late adolescence and early adulthood, the proportion of people who actually receive treatment in time is quite low,” said Dr. Krausz, an expert in epidemiology and public health.

“Too often, their first opportunity to access care results from an encounter with police or a trip to the emergency room. Enabling young adults to get help early will reduce the chances that their condition will lead to substance abuse or attempts at suicide,” Dr. Krausz added.

“We are very pleased to be partnering with UBC on this project which will use the latest technology to help young people suffering from mental illness have better access to care,” said Ms. Deacon. “The Bell Youth Mental Health IMPACT Project fits perfectly with the Bell Let’s Talk initiative and is another example of Bell partnering with leading institutions across the country, like UBC, who are looking for innovative ways to broaden the scope of work that they do to address mental health throughout our communities.”

The project will include: research into how B.C.’s young adults are currently using online mental health resources and what is lacking; testing of a web-based psychotherapy program that includes an online self-assessment tool along with self-guided exercises and techniques; creation of a similar online program for anxiety; and testing the effectiveness of various online communication channels, not only between experts and patients but also between experts and primary care providers.

At first, the project will focus on underserved communities and involve partnerships with primary care physicians, school counselors, police and family organizations to facilitate use of the platform by those who need it. Insights from these pilot studies will be used to develop a province-wide mental health web portal.

The project will leverage the UBC Faculty of Medicine’s experience in creating a sophisticated, robust communications network for its distributed medical education program, which encompasses four academic campuses and about 20 clinical sites around the province.

“The Faculty of Medicine, through its distributed medical education network, now has ample experience using technology to address the health care needs of B.C.’s population,” said Dr. Gavin Stuart, dean of the Faculty of Medicine and UBC’s vice provost health. “We are grateful that Bell has given us the opportunity to apply that experience in creating a new model for providing mental health care, one that is particularly suited to the province’s scattered population.”

The Bell Let’s Talk Mental Health Initiative is a $50-million, multi-year charitable program that promotes mental health across Canada based on four key pillars: anti-stigma, care and access, research, and workplace best practices. It’s the largest-ever corporate investment in mental health in Canada. To learn more about the Bell’s initiative, including Bell Let’s Day on February 8, 2012, please visit Bell.ca/LetsTalk.

The UBC Faculty of Medicine provides innovative programs in the health and life sciences, teaching students at the undergraduate, graduate and postgraduate levels. Its faculty members received $295 million in research funds, 54 percent of UBC’s total research revenues, in 2010-11. For more information, visit www.med.ubc.ca.

The UBC Institute of Mental Health is home to a community of clinicians and scientists who are fully committed to re-examining the field of mental health and mental illness, and to seeking new insights into the diagnosis and treatment of some of the most challenging issues in modern medicine.

Community Partnerships

The Dream Healer

The Institute is also playing an active role in organizing a series of academic lectures designed to complement the world premier of the opera, The Dream Healer, based on Timothy Findley’s Pilgrim which focuses on Carl Jung’s time at the Burghölzli Clinic.

The opera, The Dream Healer, is not just a work of biography, but also of social issues relating to total health – a concept that Jung pioneered by broadening our understanding of healing to include not only science but also the humanities and the arts.

This fundamental element is personified by blending the opera with a lecture series in a unique combination of medicine and music. The series of three lectures featuring international authorities on topic ranging from Stigma to Suicide, plus a film presentation, will be held at the Chan Centre from March 2-8, 2008 and will be open to both the academic community and general public.

Dalai Lama Centre for Peace and Education

The Institute has an ongoing partnership with the Dalai Lama Centre for Peace and Education aimed at establishing dialogues on topics of mutual interest as they pertain to mental health and the well-being of our society. Following on from the great success of organizing and presenting the September 2006 Dialogue on Happiness and Stress as Determinants of Mental Health, between HH the Dalai Lama and prominent clinical and social scientists, the Institute has co-sponsored two separate events at the Wosk Centre for Dialogue featuring, on one occasion presentations by Professor Richard Davidson University of Wisconsin, and John Helliwell, UBC, and most recently Professor Paul Ekman, UCSF, speaking about his upcoming book “Emotion and Compassion,” derived from nearly 40 hours of conversation with HHDL.

Public Education

A current focus of the Department’s Public Education program is a mental health film series called “Frames of Mind“. Its goal is to promote community education of issues pertaining to mental health and illness. This ongoing series consists of a once-a-month evening screening of a feature length dramatic film or documentary followed by an informal presentation related to the mental health issue depicted in the film. Speakers and panelists range from psychiatrists and other mental health professionals to representatives from mental health community-based and nonprofit organizations, cinema experts and mental health consumers and their family members. A moderated discussion concludes each evening, with full audience participation encouraged.

Other aspects of the series – now in its eighth year – include its rotating co-sponsorship by relevant community advocacy organizations and its ongoing evaluation by those who attend. To date, topics ranging from depression to schizophrenia to autism have now been successfully presented to over 8000 attendees. Please see website

Screenings are held at 7:30pm on the third Wednesday evening of each month at the Pacific Cinematheque Theatre, 1131 Howe Street.

Brain Talks

BrainTalks is a series of talks designed to invite you to consider emerging research about the brain. Researchers studying the brain, from various disciplines including psychiatry, neuroscience, neuroimaging, and neurology, gather to discuss current leading edge topics on the mind. The talks include:

  • dialogue around current topics in the news and popular press
  • up-to-date reviews of current literature in academic press
  • videos and/or film excerpts of relevant discoveries
  • CME credits for select talks

For a list of lecture topics, and detailed descriptions, view the website.

Recruitment

Vancouver 07_jpg

The Institute has played a major role in the recruitment of other outstanding scientists to UBC and its affiliated clinical departments:

Anthony Bailey, MB,BS, DCH, MRCPsych, FRCPsych
Professor and Chair of Child and Adolescent Psychiatry
University of British Columbia

Michael Krausz, MD, PhD, FRCPC
Professor, LEEF Chair Addiction Research
Centre for Health Evaluation & Outcome Services

Judy Illes, PhD
Canada Research Chair in Neuroethics and
Professor of Neurology,
National Core for Neuroethics,
University of British Columbia

Contact Institute of Mental Health

Please see map

UBC Institute of Mental Health

2255 Wesbrook Mall,
Vancouver, British Columbia
Canada V6T 2A1

Phone: 604-822-7310

Locate on Campus Map (& Plot Second Location) Locate on Campus Map

Director

Dr. Lakshmi N. Yatham, MBBS, FRCPC, MRCPsych (UK), MBA (Exec)

Professor and Head, UBC Department of Psychiatry

Director, Institute of Mental Health, UBC

Regional Head and Program Medical Director, VCH/PHC

 

Contact
E-mail: psychiatry.headasst@ubc.ca

Putting research to work